Literature DB >> 22446942

Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.

Alka Mary Mathai1, Monesh J Kapadia, Jacob Alexander, Lauren E Kernochan, Paul E Swanson, Matthew M Yeh.   

Abstract

The role of Foxp3-positive regulatory T cells (Foxp3 Tregs) in suppression of antitumoral immune response is well documented in patients with cancer. However, it is not known whether Foxp3 Tregs are associated with specific clinicopathologic characteristics of hepatocellular carcinoma (HCC). The aims of the present study were: (1) to investigate the relationship between Foxp3 Tregs and histologic differentiation, Edmondson-Steiner (ES) nuclear grade, vascular invasion, and pathologic stage of HCC in patients undergoing surgery for their disease; and (2) to evaluate any Foxp3 Treg-defined difference in the risk for tumor recurrence or death. The study sample included 131 histologic sections of HCC. The number of tumor-infiltrating CD3, CD8, and Foxp3 lymphocytes was assessed by immunohistochemistry. An increased Foxp3:CD3 ratio was associated with more poorly differentiated HCC (P=0.0016) and higher ES nuclear grade (P=0.0407). An increased Foxp3:CD8 ratio was also associated with poorer differentiation (P=0.0044), higher ES nuclear grade (P=0.0179), recurrence (P=0.0183), decreased overall survival (hazard ratio=1.153; 95% confidence interval, 1.019-1.304; P=0.0235), and decreased disease-free survival (hazard ratio=1.138; 95% confidence interval, 1.016-1.273; P=0.0249). Tumor size and type of surgery (surgical resection) were associated with decreased disease-free survival on univariate analysis but not on multivariate analysis. In conclusion, a higher concentration of tumor-infiltrating Foxp3 Tregs in HCC is associated with higher grade and poorly differentiated tumors and signifies an unfavorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446942     DOI: 10.1097/PAS.0b013e31824e9b7c

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  31 in total

Review 1.  Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis.

Authors:  Matteo Cescon; Valentina Rosa Bertuzzo; Giorgio Ercolani; Matteo Ravaioli; Federica Odaldi; Antonio Daniele Pinna
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  Prognostic significance of regulatory T lymphocytes in patients with hepatocellular carcinoma.

Authors:  Ai-Bin Zhang; Yi-Gang Qian; Shu-Sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2016 Dec.       Impact factor: 3.066

Review 3.  Immunosuppression in liver tumors: opening the portal to effective immunotherapy.

Authors:  P Guha; J Reha; S C Katz
Journal:  Cancer Gene Ther       Date:  2016-12-02       Impact factor: 5.987

Review 4.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.

Authors:  Tengfei Wei; Jun Zhang; Yanghua Qin; Yu Wu; Li Zhu; Longkun Lu; Gusheng Tang; Qian Shen
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

Review 6.  The prognostic value of liver tumor T cell infiltrates.

Authors:  Hadi Khan; Venu G Pillarisetty; Steven C Katz
Journal:  J Surg Res       Date:  2014-06-07       Impact factor: 2.192

7.  High intratumoral FOXP3⁺ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer.

Authors:  Tim Hanke; Nathaniel Melling; Ronald Simon; Guido Sauter; Carsten Bokemeyer; Patrick Lebok; Luigi M Terracciano; Jakob R Izbicki; Andreas H Marx
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

8.  The distribution of cutaneous metastases correlates with local immunologic milieu.

Authors:  Joshua M Schulman; Mariela L Pauli; Isaac M Neuhaus; Roberto Sanchez Rodriguez; Keyon Taravati; Uk Sok Shin; Timothy H McCalmont; Michael D Rosenblum
Journal:  J Am Acad Dermatol       Date:  2016-01-09       Impact factor: 11.527

9.  Clinical evaluation of systemic and local immune responses in cancer: time for integration.

Authors:  Dmitriy W Gutkin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2013-10-08       Impact factor: 6.968

10.  Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.

Authors:  Lupe G Salazar; Hailing Lu; Jessica L Reichow; Jennifer S Childs; Andrew L Coveler; Doreen M Higgins; James Waisman; Kimberly H Allison; Yushe Dang; Mary L Disis
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.